After the FDA gave Sarepta "another shot at an accelerated approval" by requesting the company provide dystrophin data from biopsies already obtained from the ongoing PROMOVI confirmatory study of eteplirsen, Janney Capital analyst Debjit Chattopadhyay raised his probability of accelerated approval for the drug to 55%. While the stock could rise above $50 per share on approval, there is still downside risk if the dystrophin data disappoints, Chattopadhyay tells investors. The analyst raised his fair value estimate on Sarepta shares to $25 from $18 but keeps a Neutral rating on the stock.